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Abstract 
Background: Investigation on the rapid disease progression after immune checkpoint 
inhibitor therapy in urologic malignancies is lacking. 
Objective: The objective was to evaluate the immediate progressive disease (PD) after 
nivolumab therapy for pretreated metastatic renal cell carcinoma. 
Patients and Methods: Forty patients were retrospectively evaluated. Immediate PD was 
clinically or objectively diagnosed. Clinical diagnosis was defined as an acceleration of 
symptoms directly caused by tumor growth or systematic worsening of the general 
condition such as cachexia. Objective diagnosis was based on imaging evaluation using 
Response Evaluation Criteria in Solid Tumors version 1.1 and development within the 
initial two cycles of nivolumab therapy. 
Results: Seven patients (17.5%) experienced immediate PD; thereafter, all patients died 
of cancer. The median time from therapy initiation to development was 14 days. 
Progression-free and overall survival after nivolumab therapy were significantly shorter 
in patients with immediate PD compared with those without immediate PD (progression-
free survival: 0.66 vs. 10.5 months, p<0.0001; overall survival: 1.41 months vs. not 
reached, p<0.0001). Furthermore, female sex (p=0.0434), poor MSKCC risk (p=0.0263), 
and shorter duration of prior-line time to progression (p=0.0218) were associated with 
immediate PD. 
Conclusions: The development of immediate PD in a subset of patients could deteriorate 
patient prognosis. Sex, MSKCC risk, and duration of prior-line time to progression might 
be involved in the development. Although these findings had limited evidence due to the 
study design, the data have the potential to improve treatment strategy. Therefore, 
prospective studies should further assess these findings.   
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Key points 
1. Rapid disease progression after immune checkpoint inhibitor therapy has been 
discussed in various types of cancer. 
 
2. Immediate progressive disease developed in 17.5% of metastatic renal cell carcinoma 
patients after nivolumab therapy and deteriorated patient prognoses. 
 
3. Female sex, poor risk, and shorter duration of prior-line time to progression were 
potential predictive factors of development of immediate progressive disease. 
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1. Introduction 
The immune checkpoint inhibitor (ICI) nivolumab has been approved for previously 
treated patients with metastatic renal cell carcinoma (mRCC) based on a pivotal phase III 
trial [1]. The CheckMate 025 study demonstrated that nivolumab had an overall survival 
(OS) benefit and more favorable tolerability compared with everolimus [1-4]; therefore, 
the treatment strategy for mRCC has dramatically changed [5, 6]. 
As experience with the use of nivolumab increases, a unique phenomenon specific to 
ICIs has come to light. Rapid disease progression after therapy initiation, namely 
“hyperprogression,” has been recently discussed because ICIs can have a deleterious 
effect of accelerating the disease in a subpopulation [7-9]. It is suggested that this 
undesired phenomenon can develop regardless of cancer type or prior corresponding 
therapies [7, 9, 10]. A recent study showed preliminary data regarding hyperprogression 
in patients with advanced head and neck squamous cell carcinoma during anti-
programmed cell death 1 (PD-1)/PD-ligand 1 (PD-L1) therapy [8]. 
For now, hyperprogression is defined as the tumor growth rate incorporating the time 
of the event, allowing for a quantitative and dynamic evaluation of the tumor burden along 
the treatment sequence [8, 7, 9]. This definition is highly objective and reproducible; 
however, some patients can be excluded from analyses because rapid clinical disease 
progression does not allow imaging evaluation [7]; thus, the detection of “clinical 
hyperprogression” may be missed. Most importantly, such cases always exist in a real-
world setting. However, the number of studies regarding the phenomenon is limited in 
urologic malignancies, including cases involving mRCC. 
Herein, we evaluated mRCC patients with rapid disease progression clinically or 
objectively diagnosed using imaging evaluation with immediate progressive disease 
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(immediate PD), which is defined as an acceleration of cancer-related symptoms, after 
nivolumab therapy initiation. The prognostic impact and risk factors of immediate PD 
were analyzed.   
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2. Materials and methods 
2.1. Study design 
In our department and its affiliated institution, 42 patients received nivolumab 
administration at least once for previously treated mRCC between June 2013 and October 
2017. After exclusion of two patients whose clinical data were lacking, the remaining 40 
patients were evaluated in this study. 
The Internal Ethics Review Boards of the Tokyo Women’s Medical University and 
Tokyo Women’s Medical University Medical Center East approved this multi-
institutional retrospective study (ID: 4717), which was performed in accordance with the 
principles of the Declaration of Helsinki. All clinical and laboratory data were extracted 
from the electronic database and patient medical records. 
 
2.2. Protocol of nivolumab therapy 
The protocol of nivolumab therapy is based on that used in the previous pivotal study 
[1]. Briefly, nivolumab was intravenously administered every two weeks. Dose 
modifications were not permitted in any cases. Otherwise, an interval of administration 
could be modified according to patients’ conditions or cases with onset of drug-induced 
adverse events. In all cases, nivolumab was administered in patients with previously 
treated mRCC based on the consensus guidelines [5]. A detailed regimen of sequential 
molecular-targeted therapy is described in our previous studies [11-13]. 
Post-treatment follow-up scans obtained using computed tomography or magnetic 
resonance imaging of the chest, abdomen, and pelvis were taken at regular 4- to 12-week 
intervals, depending on the patients’ conditions. Drugs were administered until disease 
progression or intolerable adverse events were observed. 
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2.3. Definition of immediate PD and evaluation of objective response during nivolumab 
therapy 
We defined immediate PD as progressive disease that was clinically or objectively 
diagnosed using imaging examination with an acceleration of cancer-related symptoms. 
In addition, immediate PD was defined as a disease that developed within the initial two 
cycles of nivolumab therapy and required the permanent termination of nivolumab 
therapy. 
Specifically, the clinical definition of immediate PD was based on the cancer-related 
symptoms. Cancer-related symptom was defined as a symptom that was physically or 
directly caused by tumor growth or infiltration of surrounding tissues. For example, when 
a patient had back pain caused by a spinal metastatic tumor growth, this pain was defined 
as a cancer-related symptom. Meanwhile, worsening of the general condition such as 
cancer cachexia that was indirectly or systematically caused by disease progression was 
considered as clinical immediate PD. 
The definition of objective immediate PD was assessed using imaging evaluation 
based on the standard Response Evaluation Criteria in Solid Tumors (RECIST) version 
1.1 [14]. We evaluated the tumor response of target lesions, non-target lesions, and new 
lesions, with each classification defined as follows: target lesion growth was defined as 
an increase of ≥20% in the sum of diameters of the target lesions, taking the smallest sum 
observed in the study as reference. In addition to a relative increase of 20%, the sum had 
to demonstrate an absolute increase of at least 5 mm. The unequivocal progression of 
existing non-target lesions and the appearance of new malignant lesions were defined as 
disease progression. 
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2.4. Statistical analysis 
Continuous variables were analyzed using the Mann-Whitney U test, and categorical 
variables were analyzed using the Fisher’s exact test. Time to progression (TTP) and 
progression-free survival (PFS) were defined as the time from prior therapy initiation to 
the date of progression and from nivolumab therapy initiation to the date of progression, 
respectively. OS was defined as the time from nivolumab therapy initiation to the date of 
death from any cause. Survival was calculated using the Kaplan-Meier method and 
compared using the log-rank test. Univariate logistic regression analysis was used to 
identify risk factors for immediate PD development. Risk was expressed as odds ratio 
(ORs) and 95% confidence intervals (CIs). All statistical analyses were conducted using 
JMP software (version 11; SAS Institute Inc., Cary, NC, USA), and p<0.05 indicated 
statistical significance. 
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3. Results 
3.1. Patient background 
In total, immediate PD developed in seven patients (17.5%). The median time from 
nivolumab therapy initiation to immediate PD onset was 14 days (interquartile range: 12-
16 days). Table 1 shows the baseline patient characteristics. At the time of nivolumab 
therapy initiation, 30 patients (75.0%) were classified into the intermediate MSKCC risk 
group (based on the Motzer’s risk classification [15]). Nivolumab was administered as a 
second-line agent in 16 patients (40.0%), and tyrosine kinase inhibitors were frequently 
used as the first-line targeted therapy (n=39, 97.5%). The patients were divided into two 
groups based on immediate PD development; poor performance status (≥2) (57.1% vs. 
6.1%, p=0.0006), poor MSKCC risk (57.1% vs. 15.2%, p=0.0337), and shorter duration 
of TTP prior to nivolumab (<6 months) (85.7% vs. 30.3%, p=0.0109) were frequently 
observed in patients with immediate PD compared to those without immediate PD. 
Furthermore, the percentage of female patients tended to be higher in the immediate PD 
group (57.1% vs. 18.2%, p=0.052). There were no significant differences in any other 
clinicopathological factors between the two groups (all p>0.05). As expected, the follow-
up duration was significantly shorter in patients with immediate PD (median: 1.41 vs. 
10.0 months, p=0.0002). 
 
3.2. Patient survival after immediate PD development 
During the follow-up, 25 (62.5%) and 12 (30.0%) patients among the total number of 
patients experienced disease progression and death due to any cause. Figure 1 shows PFS 
and OS after nivolumab therapy initiation according to immediate PD development. 
Patients with immediate PD had a significantly shorter duration of PFS and OS compared 
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to those without immediate PD (median PFS: 0.66 [95% CI: 0.13-1.38] vs. 10.5 [95% CI: 
7.30-36.6] months, p<0.0001; OS: 1.41 months [95% CI: 0.72-2.99] vs. not reached [95% 
CI: 21.4-not reached], p<0.0001). 
 
3.3. Risk factors for immediate PD development 
Table 2 shows the results of the univariate analysis for risk factors of immediate PD 
development. The univariate analysis showed that female sex (OR: 6.00, 95% CI: 1.05-
34.1, p=0.0434), poor MSKCC risk (OR: 7.47, 95% CI: 1.27-44.0, p=0.0263), and shorter 
duration of prior TTP (OR: 13.8, 95% CI: 1.46-130.1, p=0.0218) were associated with 
immediate PD development. 
 
3.4. Individual clinical profiles in patients with immediate PD 
Table 3 shows individual clinical profiles in the seven patients with immediate PD 
development. In four patients, performance status was poor and the corresponding risk 
was classified into poor risk. Acute respiratory failure due to rapid lung metastasis was 
observed in three patients. Only one patient (patient 6) received sequential targeted 
therapy after immediate PD and happened to have longer survival compared to the other 
patients (Figure 2). As for components of immediate PD, target lesion growth 
with/without appearance of new lesions was observed in three patients (patients 2, 6, and 
7) (Supplementary Figure 1), whereas the appearance of new lesions with/without non-
target lesion growth was found in three patients (patients 1, 4 and 5) (Figure 3). In patient 
3, although imaging evaluation of immediate PD was not conducted, the cancer-related 
cachexia was rapidly accelerated, and we determined that the patient could be included 
in this study based on the definition of immediate PD.   
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4. Discussion 
In this study, seven (17.5%) of 40 patients experienced immediate PD after nivolumab 
therapy for mRCC. Immediate PD developed with substantial incidence and seriously 
deteriorated patient prognoses. Female sex, poor risk, and shorter duration of prior TTP 
were indicated to be associated with immediate PD. To the best of our knowledge, this is 
the first study to evaluate the prognostic impact and predictive factors for rapid disease 
progression after ICI therapy for mRCC. Because immediate PD was defined as rapid 
disease progression diagnosed clinically or objectively in this study, we believe that the 
present data can reflect the situation in real-world clinical practice. 
Champiat et al. [7] reported that 9% of patients were considered to have 
hyperprogression with various types of cancers after corresponding prior therapies. In 
their cohort, however, hyperprogression was not observed in patients with mRCC (0/9 
patients). In another study, a higher proportion (29%) of patients underwent 
hyperprogression after anti-PD-1/PD-L1 therapy for advanced head and neck squamous 
cell carcinoma [8]. In this context, we focused on clinical disease progression additional 
to the imaging evaluation, and the findings were believed to reflect the real-world clinical 
situations. 
Patient prognosis after immediate PD appeared to be extremely poor, which was 
consistent with the findings of previous studies [8, 16]. Only one patient (patient 6) 
received sequential targeted therapy, and the prognosis appeared to be relatively favorable. 
This might indicate that, even after immediate PD, sequential therapy was a feasible 
option in this patient [13, 17, 18]. However, the possible benefit of sequential therapy 
should be assessed via further prospective controlled studies with a larger sample. 
We found that female sex, poor risk, and shorter prior TTP might be used to predict 
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the immediate PD development. Thus, upon further validation of data, consideration of 
these factors has the potential to avoid immediate PD and contribute to the improvement 
of treatment strategies. Male sex was previously indicated as a preferable factor for OS 
[1], and a recent systematic review and meta-analysis study also showed that therapeutic 
efficacy of ICI therapy was sex-dependent [19]. In addition, sex-related differences of 
immune response in cancer microenvironment have been indicated [20, 21]. A shorter 
prior TTP might reflect a high aggressiveness of the disease. Thus, possibly, the rapidly 
growing tumor cannot be suppressed even by nivolumab, which has a higher objective 
response rate than molecular-targeted therapies [1, 22]. 
Interestingly, patient 5 of the present study developed a cerebral hemorrhage from a 
new brain metastasis (Table 3). In this case, the brain metastasis could have existed before 
nivolumab was started, albeit undetected because of the lack of neurological symptoms. 
It may suggest that an untreated metastatic brain disease can be a factor in the critically 
deteriorating patient prognosis, as reported in a previous study regarding non–small-cell 
lung cancer [23]. 
It is difficult to identify whether the rapid disease progression, namely 
hyperprogression or immediate PD, is caused by nivolumab or just reflected the nature of 
aggressive disease. The disease treated with nivolumab may have already hovered 
inherent aggressiveness or resistance to any therapies. Another concern is that the 
withdrawal of prior targeted therapy after a long-term response may reflect the rapid 
disease progression [24, 25]. The immune microenvironment plays a dual role: both anti-
tumor and cancer-promoting effects [26-29]. Furthermore, changes in immune-modifying 
factors encoding genomic or epigenetic alterations can affect the variability in the tumor 
response [9, 30-32]. Once we can determine whether the immune microenvironment is 
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unexpectedly altered and becomes “tolerant to cancer” after nivolumab therapy, we can 
demonstrate that immediate PD is caused by nivolumab. However, it is merely a 
conjecture at this point, and further basic research investigating the immune 
microenvironment alterations during nivolumab therapy is needed to elucidate the 
mechanism of immediate PD. 
In addition, ICI therapy has been approved in first-line setting for untreated advanced 
renal cancer according to a result from a phase III trial “CheckMate 214” [22]. Thus, we 
should monitor whether the same phenomenon develops even in the first-line setting 
where there is no influence of prior therapies. 
This study has several limitations. First, this was a retrospective study conducted 
using limited sample with heterogeneous patient background such as regimens of prior 
therapies in only two institutions. Therefore, the findings could be affected by unrevealed 
factors or biases. In addition, only univariate analysis was carried out due to the limited 
sample size and few incidences of immediate PD development. Second, we did not 
evaluate the possibilities for pseudoprogression in the seven patients because subsequent 
imaging evaluation, which were needed for diagnosis of pseudoprogression [16, 33], was 
not performed because of the patients’ clinical course. However, we considered 
possibility of pseudoprogression to be low because the distinctive worsening of 
symptoms was concomitant with the progression of the disease in all the patients. Third, 
there was some time lag between time at baseline imaging and time at therapy initiation, 
as shown in Table 3. Thus, the disease might have already progressed before nivolumab 
therapy, and this could raise one interpretation that the nature of disease was in part 
involved in immediate PD. Taken together, the present finding should be assessed in 
future prospective studies with homogeneous treatment profiles.   
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5. Conclusions 
This study showed that immediate PD developed in a subset of mRCC patients after 
nivolumab therapy and could significantly deteriorate patient prognoses. Furthermore, 
female sex, poor risk, and shorter prior TTP might be effective predictive factors for 
immediate PD development. Although these findings have limited evidence due to the 
nature of study design, the data have potential to improve treatment strategy of mRCC in 
ICI treatment era. Therefore, further prospective studies are required to assess these 
findings.   
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Figure legends 
Figure 1. Progression-free and overall survival after nivolumab therapy initiation 
according to immediate PD development 
Progression-free and overall survival were significantly shorter in patients with 
immediate PD (n=7) compared to those without immediate PD (n=33) (median 
progression-free survival: 0.66 vs. 10.5 months, p<0.0001; overall survival: 1.41 months 
vs. not reached, p<0.0001). 
PD, progressive disease; CI, confidence interval; N.A., not applicable 
 
Figure 2. Time to immediate PD onset and subsequent patient prognosis shown by a 
swimmer plot 
All patients died of cancer. 
 
Figure 3. Changes in the sum of the diameters of the target lesions and the objective 
response rate from baseline to initial evaluation 
Patient 4 was excluded due to a lack of imaging evaluation after immediate PD. Initial 
imaging evaluation was performed at the time of immediate PD development in six 
patients. 
 
1 
 
Table 1. Baseline patient characteristics according to the presence of immediate PD development 
Variable All (n=40) With immediate 
PD (n=7) 
Without immediate 
PD (n=33) 
p 
Sex 
   
0.052 
Female (reference: male) 10 (25.0%) 4 (57.1%) 6 (18.2%) 
 
Age, years 
   
0.432 
≥65 (reference: <65) 23 (57.5%) 3 (42.9%) 20 (60.6%) 
 
Histology 
   
1a 
Clear-cell carcinoma 33 (82.5%) 6 (85.7%) 27 (81.8%) 
 
Papillary renal cell carcinoma type II 2 (5.0%) 0 2 (6.1%)  
Xp 11.2 translocation renal cell carcinoma 2 (5.0%) 0 2 (6.1%)  
Mucinous tubular and spindle cell carcinoma  1 (2.5%) 1 (14.3%) 0  
Others/unknown 2 (5.0%) 0 2 (6.1%)  
Performance status at nivolumab therapy initiation    0.0006b 
0 27 (67.5%) 1 (14.3%) 26 (78.8%)  
1 7 (17.5%) 2 (28.6%) 5 (15.2%)  
≥2 6 (15.0%) 4 (57.1%) 3 (6.1%)  
MSKCC risk at nivolumab therapy initiation 
   
0.0337c 
Favorable 1 (2.50%) 0 1 (3.03%) 
 
Intermediate 30 (75.0%) 3 (42.9%) 27 (81.8%) 
 
Poor 9 (22.5%) 4 (57.1%) 5 (15.2%) 
 
2 
 
Number of prior therapies 
   
1 
1 (reference: ≥ 2) 16 (40.0%) 3 (42.9%) 13 (39.4%) 
 
Prior cytokine therapy 
   
1 
With 7 (17.5%) 1 (14.3%) 6 (18.2%) 
 
First-line targeted therapy 
   
1d 
TKI 39 (97.5%) 7 (100%) 32 (97.0%) 
 
Sorafenib 14 (35.0%) 1 (14.3%) 13 (39.4%) 
 
Sunitinib 18 (45.0%) 4 (57.1%) 14 (42.4%) 
 
Axitinib 2 (5.00%) 0 2 (6.06%) 
 
Pazopanib 5 (12.5%) 2 (28.6%) 3 (9.09%) 
 
mTORi 1 (2.50%) 0 1 (3.03%) 
 
Temsirolimus 1 (2.50%) 0 1 (3.03%) 
 
Everolimus 0 0 0 
 
Serum CRP level, mg/dL 
   
0.387 
≥1.0 (reference: < 1.0) 26 (65.0%) 6 (85.7%) 20 (60.6%) 
 
First-line TTP, months 
   
0.679 
<6 (reference: ≥6) 14 (35.0%) 3 (42.9%) 11 (33.3%) 
 
Prior-line TTP, months 
   
0.0109 
<6 (reference: ≥6) 16 (40.0%) 6 (85.7%) 10 (30.3%) 
 
Number of metastatic sites 
   
0.681 
Multiple (reference: single) 24 (60.0%) 5 (71.4%) 19 (57.6%) 
 
Liver metastasis 
   
0.0878 
3 
 
Presence (reference: absence) 7 (17.5%) 3 (42.9%) 4 (12.1%) 
 
Follow-up period, monthse 9.14 (4.43-12.1) 1.41 (1.25-2.99) 10.0 (7.27-14.3) 0.0002 
a Clear-cell carcinoma vs. non-clear-cell carcinoma. b ≤1 vs. ≥2. c Favorable/intermediate vs. poor. d TKI vs. mTORi. e Median (interquartile range). 
PD, progressive disease; MSKCC, Memorial Sloan Kettering Cancer Center; TKI, tyrosine kinase inhibitor; mTORi, mammalian target of rapamycin inhibitor; CRP, 
C-reactive protein; TTP, time to progression.  
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Table 2. Univariate analysis for risk factors of immediate PD development 
Variable Univariate OR (95% CI) p 
Sex 
  
Female (reference: male) 6 (1.05-34.1) 0.0434 
Age, years 
  
≥65 (reference: <65) 0.49 (0.09-2.54) 0.394 
Histology 
  
Clear-cell carcinoma (reference: non-clear-cell carcinoma) 1.33 (0.134-13.2) 0.806 
MSKCC risk at nivolumab therapy initiation 
  
Poor (reference: favorable/intermediate) 7.47 (1.27-44.0) 0.0263 
Number of prior therapies 
  
1 (reference: ≥2) 1.15 (0.22-6.02) 0.865 
Prior cytokine therapy 
  
With 0.75 (0.076-7.44) 0.806 
First-line targeted therapy 
  
mTORi (reference: TKI) 1.14E-06 0.995 
Serum CRP level, mg/dL 
  
≥1.0 (reference: <1.0) 3.9 (0.42-36.2) 0.232 
First-line TTP, months 
  
<6 (reference: ≥6) 1.50 (0.28-7.91) 0.633 
Prior-line TTP, months 
  
5 
 
<6 (reference: ≥6) 13.8 (1.46-130.1) 0.0218 
Number of metastatic sites 
  
Multiple (reference: single) 1.84 (0.31-10.9) 0.501 
Liver metastasis 
  
Presence (reference: absence) 5.44 (0.88-33.8) 0.0691 
OR, odds ratio; CI, confidence interval. 
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Table 3. Individual clinical profiles in patients with immediate PD 
Patie
nt 
Age 
(year
s)/sex 
Prior 
therapy 
to 
nivolum
ab 
Line of 
nivolum
ab 
Comorbi
dity 
Metastat
ic sites 
MSKCC PS TTP of 
prior 
therapy, 
months 
Days from 
therapy 
initiation to 
event (TTP of 
nivolumab) 
Days from 
baseline 
imaging to 
event 
Events as 
immediate 
PD 
Patterns 
of PD 
according 
to the 
RECIST 
1 63/M Cytokine
s, 
pazopani
b, 
axitinib 
Fourth-
line  
Dyslipid
emia  
Lung, 
liver, 
adrenal, 
kidney 
Intermed
iate  
0 3.65 13 16 Carcinoma
tous 
lymphangi
osis due to 
rapid lung 
metastasis 
Non-target 
lesion 
growth and 
appearance 
of new 
lesions 
2 66/F Pazopani
b, 
sorafenib
, axitinib 
Fourth-
line 
Hyperten
sion 
Bone, 
liver, 
lymph 
node 
Poor 2 15.8 12 16 Acute 
paralysis 
due to 
rapid 
tumor 
growth of 
spinal 
metastasis 
Target 
lesion 
growth 
3 63/F Sunirinib Second-
line 
None Lymph 
node 
Poor 2 5.92 16 65 Rapid 
cancer-
related 
Not 
evaluated  
7 
 
cachexic 
acceleratio
n 
4 71/F Sunitinib
, axitinib 
Third-
line 
Colon 
cancera 
Lung, 
kidney, 
lymph 
node 
Poor 2 4.54 2 14 Acute 
respiratory 
failure due 
to rapid 
lung 
metastasis 
Non-target 
lesion 
growth and 
appearance 
of new 
lesions 
5 64/M Sunitinib
, axitinib, 
everolim
us 
Fourth-
line 
None Lung, 
liver, 
renal 
pelvis, 
lymph 
node 
Poor 2 1.12 14 42 Cerebral 
hemorrhag
e from 
brain 
metastasis  
Appearanc
e of new 
lesions 
6 41/M Sunitinib Second-
line 
None  Lymph 
node 
Intermed
iate 
1 2.47 14 28 Back pain 
due to 
rapid 
tumor 
growth of 
retroperito
neal lymph 
node 
Target 
lesion 
growth and 
appearance 
of new 
lesions 
8 
 
metastasis 
7 75/F Sorafeni
b 
Second-
line 
None Lung, 
lymph 
node 
Intermed
iate  
1 3.06 28 47 Acute 
respiratory 
failure due 
to rapid 
lung 
metastasis 
Target 
lesion 
growth and 
appearance 
of new 
lesions 
Medi
an 
(inter
quart
ile 
rang
e) 
64 
(63-
71) 
     2 
(1-
2) 
3.65 
(2.47-
5.92) 
14 (12-16) 28 (16-47)   
a Treated 10 years ago for an early-stage cancer, and the disease appeared to be in remission. 
PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors. 
With:           0.66 months (95% CI: 0.13–1.02)
Without:     10.5 months (95% CI: 7.30–36.6)
p < 0.0001
With:        1.41 months (95% CI: 0.72–2.99)
Without:   not reached (95% CI: 21.4–N.A.)
p < 0.0001
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Supplementary Figure 1. Representative imaging showing immediate PD in 
two cases
(A) In patient 2, a spinal metastasis at the first lumbar vertebra grew.
(B) In patient 6, retroperitoneal metastases grew and spread.
Ao, aorta; L, liver; S, spleen.
